Chronic‐active antibody‐mediated rejection with or without donor‐specific antibodies has similar histomorphology and clinical outcome – a retrospective study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Transplant International

• Publication date

  2018-04-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/tri.13154PMID 29570868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Banff

  2019cited by this paper
• The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials

  2018cited by this paper
• Transplant glomerulopathy

  2018cited by this paper
• Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies.

  2016cited by this paper
• Identifying Subphenotypes of Antibody‐Mediated Rejection in Kidney Transplants

  2016cited by this paper
• The Revised (2013) Banff Classification for Antibody‐Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations

  2016cited by this paper
• The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

  2016cited by this paper
• 2013 Banff Criteria for Chronic Active Antibody‐Mediated Rejection: Assessment in a Real‐Life Setting

  2016cited by this paper
• Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy

  2015cited by this paper
• Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.

  2015cited by this paper
• Donor-Specific Antibodies, C4d and Their Relationship With the Prognosis of Transplant Glomerulopathy

  2015cited by this paper
• Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions

  2014cited by this paper
• Transplant Glomerulopathy: The Interaction of HLA Antibodies and Endothelium

  2014cited by this paper
• The Histology of Kidney Transplant Failure: A Long-Term Follow-Up Study

  2014cited by this paper
• The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy.

  2013cited by this paper
• On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-to-lot variations in MFI.

  2013cited by this paper
• Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation

  2013cited by this paper
• Advances in the understanding of transplant glomerulopathy.

  2013cited by this paper
• Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection

  2012cited by this paper
• Transplant glomerulopathy: it's not always about chronic rejection.

  2011cited by this paper
• Significance of C4d Banff Scores in Early Protocol Biopsies of Kidney Transplant Recipients with Preformed Donor‐Specific Antibodies (DSA)

  2011cited by this paper
• Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy.

  2011cited by this paper
• Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy.

  2011cited by this paper
• Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody‐Mediated Damage Despite Lack of C4d Staining

  2009cited by this paper
• De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure

  2009cited by this paper
• Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

  2008cited by this paper
• Transplant Glomerulopathy

  2008cited by this paper
• Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)

  2007cited by this paper
• Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining.

  2007cited by this paper
• Transplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody

  2007cited by this paper
• Applied multilevel analysis : a practical guide

  2006cited by this paper
• Transplant Glomerulopathy, Late Antibody‐Mediated Rejection and the ABCD Tetrad in Kidney Allograft Biopsies for Cause

  2006cited by this paper
• Banff 2003 Meeting Report: New Diagnostic Insights and Standards

  2004cited by this paper
• Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy1

  2003cited by this paper
• Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1

  2003cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper

• STAR 2025 innate working group: the potential role of innate allorecognition in kidney allograft damage.

  2025cites this paper
• Absence of IL-6 Receptor Blockade Effect on the Outcomes of Transplant Glomerulopathy in the Absence of Anti-HLA Donor-specific Antibodies

  2024cites this paper
• Immunological harmony: the dynamic influence of cellular and humoral immunity on pregnancy success

  2024cites this paper
• MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and Rejection

  2023cites this paper
• Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots

  2023cites this paper
• Pathophysiology of Rejection in Kidney Transplantation

  2023cites this paper
• Mesangiolysis in Pathological Chronic Active Antibody-Mediated Rejection in Kidney Transplant Biopsies

  2023cites this paper
• Tocilizumab for treatment of chronic active antibody‐mediated rejection in kidney transplant recipients

  2023cites this paper
• Using Regression Equations to Enhance Interpretation of Histology Lesions of Kidney Transplant Rejection

  2023cites this paper
• Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe

  2023cites this paper
• A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.

  2022cites this paper
• Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation

  2022cites this paper
• Banff Human Organ Transplant Transcripts Correlate with Renal Allograft Pathology and Outcome: Importance of Capillaritis and Subpathologic Rejection

  2022cites this paper
• Antibody-Mediated Rejection in Kidney Transplantation: A Retrospective Study on the Impact of Donor-Specific Antibodies and on the Timing of Diagnosis

  2022cites this paper
• Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients

  2022cites this paper
• Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms

  2022cites this paper
• Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection

  2022cites this paper
• Allorecognition and the spectrum of kidney transplant rejection.

  2021cites this paper
• Risk factors, histopathological features and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies.

  2021cites this paper
• The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection

  2021cites this paper
• Histologic Antibody-Mediated Kidney Allograft Rejection in the Absence of Donor Specific HLA Antibodies.

  2021cites this paper
• Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection

  2021influential citation
• The causes and frequency of kidney allograft failure in a low-resource setting: observational data from Iraqi Kurdistan

  2021cites this paper
• Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys.

  2021cites this paper
• ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.

  2020cites this paper
• Clinical Relevance of Arteriolar C4d Staining in Patients With Chronic-active Antibody-mediated Rejection: A Pilot Study

  2020cites this paper
• The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation

  2020cites this paper
• Delayed Graft Function and Acute Rejection in Kidney Transplant Patients with Positive Panel-Reactive Antibody and Negative Donor-Specific Antibodies

  2020cites this paper
• The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody‐mediated rejection

  2020cites this paper
• Association between transplant glomerulopathy and graft outcomes following kidney transplantation: A meta-analysis

  2020cites this paper
• Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?

  2020cites this paper
• Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation.

  2019cites this paper
• The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage -

  2019cites this paper
• Banff lesions and renal allograft survival in chronic-active antibody mediated rejection.

  2019cites this paper
• Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection.

  2019cites this paper
• Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

  2018cites this paper